Premium
The Use of Tegaserod in Critically ill Patients with Impaired Gastric Motility
Author(s) -
Banh Hoan Linh,
MacLean Charles,
Topp Trevor,
Hall Richard
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.02.002
Subject(s) - tegaserod , cisapride , gastroparesis , medicine , domperidone , gastric emptying , metoclopramide , partial agonist , intensive care unit , irritable bowel syndrome , intensive care medicine , adverse effect , parenteral nutrition , gastroenterology , agonist , stomach , vomiting , receptor , dopamine
Studies have shown that early enteral nutrition in critically ill patients reduces the incidence of morbidity and death. Nonetheless, intolerance to gastric enteral nutrition is common in these patients as a result of gastroparesis. The use of prokinetic agents such as metoclopramide, domperidone, cisapride, and erythromycin can improve gastric emptying, but these agents are not without deleterious adverse effects. Tegaserod, a selective serotonin type 4 receptor partial agonist, was recently approved for treatment of women with irritable bowel syndrome. On the basis of tegaserod's mechanism of action, it was hypothesized that tegaserod may accelerate the return of gastric function in intensive care unit patients with gastroparesis. It would thus provide an additional agent for the management of gastroparesis with a more favorable safety profile. We present 3 case reports of the successful use of tegaserod in intensive care unit patients with impaired gastric motility. To our knowledge, the use of tegaserod in this setting has not been reported or studied previously. Clinical Pharmacology & Therapeutics (2005) 77 , 583–586; doi: 10.1016/j.clpt.2005.02.002